跳转至内容
Merck
CN

268569

三甲基铝 溶液

2.0 M in hexanes

别名:

Trimethylalane

登录 查看组织和合同定价。

选择尺寸


关于此项目

线性分子式:
(CH3)3Al
化学文摘社编号:
分子量:
72.09
UNSPSC Code:
12352103
NACRES:
NA.22
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
3587197
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/3CH3.Al/h3*1H3;

SMILES string

C[Al](C)C

InChI key

JLTRXTDYQLMHGR-UHFFFAOYSA-N

form

liquid

concentration

2.0 M in hexanes

density

0.683 g/mL at 25 °C

Quality Level

正在寻找类似产品? 访问 产品对比指南

General description

Trimethylaluminum is a Lewis acid having wide applications in organic synthesis. It is employed in organic reactions like cross-coupling reaction, methylenation, carboalumination, cyclopropanation, and rearrangement reactions. Tebbe Reagent (methylenation agent) can be prepared in situ by reacting trimethylaluminum with dichlorobis(cyclopentadienyl)titanium.

Application

与 4-溴-2,6-二叔丁基苯酚(货号394378)一起用于通过环氧化物的选择性重排制备各种羰基化合物。

signalword

Danger

target_organs

Central nervous system

supp_hazards

存储类别

4.2 - Pyrophoric and self-heating hazardous materials

flash_point_f

-0.4 °F - closed cup

flash_point_c

-18 °C - closed cup

Hazard Classifications

Aquatic Chronic 2 - Asp. Tox. 1 - Eye Dam. 1 - Flam. Liq. 2 - Pyr. Liq. 1 - Repr. 2 - Skin Corr. 1B - STOT SE 3 - Water-react. 1

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Tetrahedron, 47, 6983-6983 (1991)
Tetrahedron Letters, 30, 5607-5607 (1989)
Trimethylaluminum
Encyclopedia of Reagents for Organic Synthesis, Second Edition (2007)
Mahtab Farzin et al.
Pathology, 47(4), 302-307 (2015-05-06)
BRCA1-associated protein 1 (BAP1) is a tumour suppressor gene frequently inactivated in mesothelioma, rarely also in association with germline mutation. BAP1 mutations have been associated with improved prognosis and distinct clinicopathological features. We sought to determine the clinicopathological significance of
J L L Robinson et al.
Oncogene, 33(50), 5666-5674 (2013-12-03)
Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical challenge with new generation second-line hormonal therapies affording limited improvement in disease outcome. As the androgen receptor (AR) remains a critical driver in CRPC, understanding the determinants of its transcriptional

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持